At Swedish biotech BioInvent, early-stage data on two anti-tumor necrosis factor receptor 2 (TNFR2) antibodies are starting to show promise. Presenting at the annual Society for Immunotherapy for Cancer conference, BioInvent was able to reveal that its candidates BI-1910 and BI-1808 both demonstrated anticancer effects in recent studies.
BI-1910 indicated broad anti-tumor activity in preclinical studies, activating T-cells and natural killer cells and showing anti-tumor activity independent of...